NAUT
Nautilus Biotechnology, Inc. NASDAQ Listed Aug 7, 2020$0.89
+0.22%
vs $0.89
Mkt Cap $113.5M
52w Low $0.62
7.4% of range
52w High $4.31
50d MA $1.70
200d MA $2.22
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.2x
ROE
-39.5%
P/FCF
-2.2x
RSI (14)
8.90
ATR (14)
$0.11
Beta
0.99
50d MA
$1.70
200d MA
$2.22
Avg Volume
905.4K
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
2701 Eastlake Avenue East · Seattle, WA 98102 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | BMO | -0.14 | -0.11 | +18.5% | 1.66 | -3.6% | -27.7% | -13.3% | -1.0% | -5.1% | +3.4% | — |
| Apr 28, 2026 | BMO | -0.14 | -0.12 | +17.2% | 2.57 | +7.8% | +0.8% | -3.5% | +5.2% | +2.7% | +7.0% | — |
| Feb 26, 2026 | BMO | -0.14 | -0.11 | +21.4% | 2.89 | +4.5% | -16.3% | +0.0% | -4.1% | +3.9% | +8.7% | — |
| Oct 27, 2025 | BMO | -0.15 | -0.11 | +26.7% | 1.22 | +0.0% | +10.7% | +5.9% | -1.4% | +0.0% | -5.7% | — |
| Jul 31, 2025 | BMO | -0.15 | -0.12 | +22.6% | 0.76 | +5.1% | +0.0% | +0.6% | -3.0% | +1.3% | +4.9% | — |
| Apr 29, 2025 | BMO | -0.14 | -0.13 | +7.1% | 0.68 | +2.9% | +8.0% | -6.2% | -0.5% | -1.1% | +1.2% | — |
| Feb 26, 2025 | BMO | -0.16 | -0.14 | +12.5% | 1.47 | +0.0% | -2.7% | -18.2% | +11.1% | -4.6% | -2.4% | — |
| Oct 29, 2024 | BMO | -0.17 | -0.13 | +23.5% | 2.81 | -4.6% | -1.4% | -4.3% | -1.9% | +0.4% | -1.5% | — |
| Jul 30, 2024 | BMO | -0.16 | -0.14 | +12.5% | 2.74 | +0.0% | -2.6% | +1.5% | -7.4% | -3.6% | -6.6% | — |
| Apr 30, 2024 | BMO | -0.16 | -0.15 | +6.2% | 2.57 | +3.1% | -1.2% | +9.4% | -4.0% | +0.7% | +4.8% | — |
| Feb 28, 2024 | BMO | -0.16 | -0.14 | +12.5% | 2.94 | -4.8% | -4.8% | -3.9% | +1.1% | -1.1% | -3.0% | — |
| Oct 31, 2023 | BMO | -0.18 | -0.13 | +27.8% | 2.34 | +0.4% | +9.4% | +0.0% | +5.1% | +6.7% | -14.6% | — |
| Aug 2, 2023 | BMO | -0.17 | -0.13 | +23.5% | 3.15 | -4.8% | -2.2% | +1.9% | +1.6% | -5.0% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $2.42 | $2.42 | +0.0% | +0.0% | -4.1% | +3.9% | +8.7% | -6.9% |
| Dec 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $2.23 | $2.20 | -1.3% | -13.9% | +11.5% | +1.4% | -2.8% | -1.4% |
| Aug 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.08 | $3.08 | +0.0% | +1.9% | +1.6% | -5.0% | +2.6% | -0.3% |
| Aug 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.82 | $2.88 | +2.1% | +0.4% | -0.4% | +4.3% | -1.0% | -2.4% |
| Aug 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.82 | $2.88 | +2.1% | +0.4% | -0.4% | +4.3% | -1.0% | -2.4% |
| Jul 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.87 | $2.85 | -0.7% | -4.9% | +0.0% | -4.4% | +6.1% | +3.2% |
| Apr 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.19 | $4.27 | +1.9% | -0.7% | -2.6% | -3.5% | +1.0% | +1.5% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.85 | $4.90 | +1.0% | -1.4% | -1.0% | +1.5% | +0.0% | -1.7% |
| Nov 2 | TD Cowen | Maintains | Outperform → Outperform | — | $5.44 | $5.71 | +5.0% | +7.2% | +0.2% | -2.2% | -1.9% | -0.4% |
| Aug 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.65 | $7.56 | -1.2% | -2.1% | +10.1% | -9.3% | +6.7% | -5.0% |
| Jul 13 | Jefferies | Maintains | Buy → Buy | — | $10.00 | $10.16 | +1.6% | -2.0% | -3.4% | -2.7% | -1.0% | -0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | — | Sell | 384,026 | $2.35 | $902K | 971,885 | -10.82% | +1.11% |
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | — | Sell | 4,615,974 | $2.35 | $10.8M | 11,682,032 | -10.82% | +1.11% |
8-K · 2.02
!! High
Nautilus Biotechnology, Inc. -- 8-K 2.02: Earnings Results
Nautilus Biotechnology disclosed Q earnings results via press release, requiring investors to review the full filing attachment for financial performance details and operational metrics.
Jul 28
8-K
Nautilus Biotechnology, Inc. -- 8-K Filing
Nautilus Biotechnology shareholders approved annual advisory votes on executive compensation, with the next frequency vote scheduled for 2032, increasing shareholder oversight of management pay practices.
Jun 18
8-K
Nautilus Biotechnolgy, Inc. -- 8-K Filing
Nautilus Biotechnology advanced its single-molecule proteome platform through Tau proteoform analysis and expanded scientific publications, validating technology utility for investors.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Clearstead Advisors, Llc | 2,329,784 | $9M | New | Mar 2026 |
| 2 | Millennium Management | 1,273,383 | $5M | Added | Mar 2026 |
| 3 | Acadian Asset Management Llc | 741,246 | $3M | Added | Mar 2026 |
| 4 | Marshall Wace, Llp | 319,882 | $1M | Added | Mar 2026 |
| 5 | Renaissance Technologies Llc | 265,700 | $1M | Added | Mar 2026 |
| 6 | Northern Trust Corp | 107,011 | $415K | — | Mar 2026 |
| 7 | Jane Street Group, Llc | 206,837 | $403K | Added | Dec 2025 |
| 8 | Point72 Asset Management | 83,043 | $322K | Added | Mar 2026 |
| 9 | Qube Research & Technologies Ltd | 79,623 | $309K | Reduced | Mar 2026 |
| 10 | Barclays Plc | 73,325 | $285K | Added | Mar 2026 |
| 11 | Hrt Financial Lp | 65,254 | $253K | New | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 63,147 | $245K | Added | Mar 2026 |
| 13 | Citizens Financial Group Inc/ri | 50,000 | $194K | New | Mar 2026 |
| 14 | Morgan Stanley | 77,168 | $150K | Added | Dec 2025 |
| 15 | Captrust Financial Advisors | 34,003 | $132K | — | Mar 2026 |
| 16 | Ubs Group Ag | 26,903 | $104K | Added | Mar 2026 |
| 17 | Public Employees Retirement System Of Ohio | 19,300 | $75K | New | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 13,372 | $52K | Reduced | Mar 2026 |
| 19 | Vanguard Capital Wealth Advisors | 13,000 | $50K | — | Mar 2026 |
| 20 | Ctc Alternative Strategies, Ltd. | 12,397 | $48K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 18
All ↗
Valuation
Market Cap
$113.5M
Enterprise Value
$35.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.26x
P/B
0.72x
P/S
597.43x
P/FCF
-2.17x
EV/EBITDA
—
Shares Out
126.3M
Financials (TTM)
Revenue
$190K
Net Income
-$56.5M
EBITDA
-$55.0M
Free Cash Flow
-$52.0M
Op Cash Flow
-$50.7M
EPS Basic
$-0.47
EPS Diluted
$-0.45
EPS Forward
$-0.52
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$191.1M
Total Liab.
$34.1M
Total Equity
$157.0M
Cash
$103.4M
LT Debt
$26.2M
Book Value/Sh
$1.24
Debt/Equity
0.19x
Current Ratio
13.33
Quick Ratio
13.33
Returns & Growth
ROE
-39.5%
ROA
-32.1%
ROIC
-35.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+16.1%
Price Returns
2W
-8.7%
1M
-48.7%
3M
-64.5%
6M
-59.3%
12M
+25.2%
Technicals
52W High
$4.31
52W Low
$0.62
50d MA
$1.70
200d MA
$2.22
RSI (14)
8.90
ATR (14)
$0.11
Beta
0.99
Avg Volume
905K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.50
High
$2.50
Low
$2.50
Median
$2.50
Data updated apr 26, 2026 2:16pm
· Source: financialmodelingprep.com